Yahoo Finance

Novo Nordisk submits Biologics License Application (BLA) to FDA for Mim8; an investigational, prophylaxis treatment for people living with hemophilia A with or without inhibitors

If approved, Mim8 (denecimig) would offer the flexibility of treatment with a single-use, prefilled disposable pen injector with dosing options including once every month, once every two weeks, and ...
clinicaltrialsarena

MoonLake’s IL-17 inhibitor falls short of Bimzelx in HS trial

MoonLake Immunotherapeutics will still file for approval of the IL-17 with the FDA. Image credit: Piotr Swat / Shutterstock.com. MoonLake Immunotherapeutics’s stock has crashed after its hidradenitis ...
C&EN

Integrated Machine Learning and Structure-Based Virtual Screening Identify Osimertinib as a TNIK Inhibitor for Idiopathic Pulmonary Fibrosis

Centre for Artificial Intelligence Driven Drug Discovery, Faculty of Applied Sciences, Macao Polytechnic University, Macau 999078, China ...
C&EN

PARP7: an Emerging Therapeutic Target-Insights into Biological Functions and Advances in Small-Molecule Inhibitor Development

Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, China ...
Medscape

EMA Backs First FcRn Inhibitor for Myasthenia Gravis

Clinicians in Europe may soon gain access to a first-in-class neonatal Fc receptor (FcRn) inhibitor for generalized myasthenia gravis (gMG). Imaavy (nipocalimab; Janssen-Cilag International) received ...